focus -WSS

focus

author：focus 2025-09-27 09:40:22 - browse：85

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Winning ticket for $1 billion Powerball jackpot sold in California

WSS

Why Congress must ban federal programs from using QALYs

In shift, Texas to cover initial consult for Afghan baby's gene therapy

7 more heat

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

FDA early review: GLP

A preacher's new calling: Diversifying neuroscience research

leisure time

focus

leisure time

Heart attack and stroke risk calculators need revising

JPM pitch from hospitals? Revenue streams outside of patient care

Cancer drug shortages should be causing more outrage

Stories you might have missed in 2023: health, science, medicine

Hepatitis C has a cure — but many Americans still lack access to it

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

In Memoriam: Notable people who died in 2023

Hospitals struggle to profit from CAR

Wikipedia

Indian pharmaceutical industry in denial over drug

JPM pitch from hospitals? Revenue streams outside of patient care

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Study identifies new proteins linked to dementia risk 25 years later

Physician assistants need a new name. Here's what it should be

Ascension's ugly legal battle over care for poor patients in Texas

focus

hotspot

leisure time

focus